

Company Number: 440912

David Hynes Pharmacy (Roscommon) Ltd
Abridged Unaudited Financial Statements
for the financial year ended 31 August 2025

David Hynes Pharmacy (Roscommon) Ltd

CONTENTS

	Page
Directors' Responsibilities Statement	3
Balance Sheet	4
Statement of Changes in Equity	5
Notes to the Financial Statements	6 - 9

David Hynes Pharmacy (Roscommon) Ltd

DIRECTORS' RESPONSIBILITIES STATEMENT

for the financial year ended 31 August 2025

The directors are responsible for preparing the Directors' Report and the financial statements in accordance with applicable Irish law and regulations.

Irish company law requires the directors to prepare financial statements for each financial year. Under the law the directors have elected to prepare the financial statements in accordance with the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" issued by the Financial Reporting Council. Under company law, the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the assets, liabilities and financial position of the company as at the financial year end date and of the profit or loss of the company for the financial year and otherwise comply with the Companies Act 2014.

In preparing these financial statements, the directors are required to:

- select suitable accounting policies for the company financial statements and then apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- state whether the financial statements have been prepared in accordance with applicable accounting standards, identify those standards, and note the effect and the reasons for any material departure from those standards; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for ensuring that the company keeps or causes to be kept adequate accounting records which correctly explain and record the transactions of the company, enable at any time the assets, liabilities, financial position and profit or loss of the company to be determined with reasonable accuracy, enable them to ensure that the financial statements and Directors' Report comply with the Companies Act 2014. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Signed on behalf of the board

David Hynes
Director

Mariece Hynes
Director

6 March 2026

David Hynes Pharmacy (Roscommon) Ltd

BALANCE SHEET

as at 31 August 2025

	Notes	2025 €	2024 €
Fixed Assets			
Tangible assets	6	1,577,958	1,579,594
Current Assets			
Stocks	7	540,919	543,272
Debtors	8	4,968,673	4,188,225
Cash at bank and in hand		1,972,431	2,251,584
		7,482,023	6,983,081
Creditors: amounts falling due within one year	9	(392,946)	(390,698)
Net Current Assets		7,089,077	6,592,383
Total Assets less Current Liabilities		8,667,035	8,171,977
Capital and Reserves			
Called up share capital presented as equity		2	2
Retained earnings		8,667,033	8,171,975
Equity attributable to owners of the company		8,667,035	8,171,977

We as Directors of David Hynes Pharmacy (Roscommon) Ltd, state that -

- (a) the company is availing itself of the exemption provided for by Chapter 15 of Part 6 of the Companies Act 2014,
- (b) the company is availing itself of the exemption on the grounds that the conditions specified in section 358 are satisfied,
- (c) the shareholders of the company have not served a notice on the company under section 334(1) in accordance with section 334(2),
- (d) we acknowledge the company's obligations under the Companies Act 2014, to keep adequate accounting records and prepare financial statements which give a true and fair view of the assets, liabilities and financial position of the company at the end of its financial year and of its profit or loss for such a financial year and to otherwise comply with the provisions of the Companies Act 2014 relating to financial statements so far as they are applicable to the company,
- (e) the company has relied on the specified exemption contained in section 352 Companies Act 2014. The company has done so on the grounds that the company is entitled to the benefit of that exemption as a small company and the abridged financial statements have been properly prepared in accordance with section 353 Companies Act 2014 and the small companies' regime.

Approved by the board on 6 March 2026 and signed on its behalf by:

David Hynes
Director

Mariece Hynes
Director

David Hynes Pharmacy (Roscommon) Ltd
STATEMENT OF CHANGES IN EQUITY

as at 31 August 2025

	Called up share capital €	Retained earnings €	Total €
At 1 September 2023	2	7,584,554	7,584,556
Profit for the financial year	-	587,421	587,421
At 31 August 2024	2	8,171,975	8,171,977
Profit for the financial year	-	495,058	495,058
At 31 August 2025	2	8,667,033	8,667,035

David Hynes Pharmacy (Roscommon) Ltd

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 31 August 2025

1. General Information

David Hynes Pharmacy (Roscommon) Ltd is a company limited by shares incorporated and registered in Ireland. The registered number of the company is 440912. The registered office of the company is Castle Street, Roscommon, Republic of Ireland which is also the principal place of business of the company. Pharmacy The financial statements have been presented in Euro (€) which is also the functional currency of the company.

2. Summary of Significant Accounting Policies

The following accounting policies have been applied consistently in dealing with items which are considered material in relation to the company's financial statements.

Statement of compliance

The financial statements of the company for the financial year ended 31 August 2025 have been prepared on the going concern basis and in accordance with FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" (FRS 102).

Basis of preparation

The financial statements have been prepared on the going concern basis and in accordance with the historical cost convention except for certain properties and financial instruments that are measured at revalued amounts or fair values, as explained in the accounting policies below. Historical cost is generally based on the fair value of the consideration given in exchange for assets. The financial reporting framework that has been applied in their preparation is the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" issued by the Financial Reporting Council.

The company qualifies as a small company as defined by section 280A of the Companies Act 2014 in respect of the financial year, and has applied the rules of the 'Small Companies Regime' in accordance with section 280C of the Companies Act 2014.

Cash flow statement

The company has availed of the exemption in FRS 102 from the requirement to prepare a Statement of Cash Flows because it is classified as a small company.

Turnover

Turnover comprises the invoice value of goods supplied by the company, exclusive of trade discounts and value added tax.

Tangible assets and depreciation

Tangible assets are stated at cost or at valuation, less accumulated depreciation. The charge to depreciation is calculated to write off the original cost or valuation of tangible assets, less their estimated residual value, over their expected useful lives as follows:

Land and buildings freehold	-	2% Straight line
Fixtures, fittings and equipment	-	12.5% Straight line
Motor vehicles	-	12.5% Straight line

The carrying values of tangible fixed assets are reviewed annually for impairment in periods if events or changes in circumstances indicate the carrying value may not be recoverable.

Stocks

Stocks are valued at the lower of cost and net realisable value. Stocks are determined on a first-in first-out basis. Cost comprises expenditure incurred in the normal course of business in bringing stocks to their present location and condition. Full provision is made for obsolete and slow moving items. Net realisable value comprises actual or estimated selling price (net of trade discounts) less all further costs to completion or to be incurred in marketing and selling.

Trade and other debtors

Trade and other debtors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest method less impairment losses for bad and doubtful debts except where the effect of discounting would be immaterial. In such cases the receivables are stated at cost less impairment losses for bad and doubtful debts.

David Hynes Pharmacy (Roscommon) Ltd

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 31 August 2025

Trade and other creditors

Trade and other creditors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest rate method, unless the effect of discounting would be immaterial, in which case they are stated at cost.

Employee benefits

The company operates a defined contribution pension scheme. The assets of the scheme are held separately from those of the company in an independently administered fund. The company also operates a defined benefit pension scheme for its employees providing benefits based on final pensionable pay. The assets of this scheme are also held separately from those of the company, being invested with pension fund managers.

Taxation and deferred taxation

Current tax represents the amount expected to be paid or recovered in respect of taxable profits for the financial year and is calculated using the tax rates and laws that have been enacted or substantially enacted at the Balance Sheet date.

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date where transactions or events have occurred at that date that will result in an obligation to pay more tax in the future, or a right to pay less tax in the future. Timing differences are temporary differences between the company's taxable profits and its results as stated in the financial statements.

Deferred tax is measured on an undiscounted basis at the tax rates that are anticipated to apply in the periods in which the timing differences are expected to reverse, based on tax rates and laws that have been enacted or substantively enacted by the Balance Sheet date.

Government grants

Capital grants received and receivable are treated as deferred income and amortised to the Profit and Loss Account annually over the useful economic life of the asset to which it relates. Revenue grants are credited to the Profit and Loss Account when received.

Foreign currencies

Monetary assets and liabilities denominated in foreign currencies are translated at the rates of exchange ruling at the Balance Sheet date. Non-monetary items that are measured in terms of historical cost in a foreign currency are translated at the rates of exchange ruling at the date of the transaction. Non-monetary items that are measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value was determined. The resulting exchange differences are dealt with in the Profit and Loss Account.

Ordinary share capital

The ordinary share capital of the company is presented as equity.

3. Operating profit	2025	2024
	€	€
Operating profit is stated after charging/(crediting):		
Depreciation of tangible assets	50,030	49,546
Government grants received	(8,000)	(7,868)
	<u><u> </u></u>	<u><u> </u></u>

4. Employees

The average monthly number of employees, including directors, during the financial year was 25, (2024 - 24).

	2025	2024
	Number	Number
Directors	2	2
Operations	23	22
	<u><u> </u></u>	<u><u> </u></u>
	25	24
	<u><u> </u></u>	<u><u> </u></u>

David Hynes Pharmacy (Roscommon) Ltd

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 31 August 2025

5. Tax on profit

	2025 €	2024 €
(a) Analysis of charge in the financial year		
Current tax:		
Corporation tax at 12.50% (2024 - 12.50%) (Note 5 (b))	<u>73,196</u>	<u>86,248</u>
(b) Factors affecting tax charge for the financial year		
The tax assessed for the financial year differs from the standard rate of corporation tax in the Republic of Ireland 12.50% (2024 - 12.50%). The differences are explained below:		
	2025 €	2024 €
Profit taxable at 12.50%	566,570	672,496
Profit taxable at 25%	1,684	1,173
Profit before tax	<u>568,254</u>	<u>673,669</u>
Profit before tax multiplied by the standard rate of corporation tax in the Republic of Ireland at 12.50% (2024 - 12.50%)	70,821	84,062
Profit before tax multiplied by 25%	421	293
	<u>71,242</u>	<u>84,355</u>
Effects of:		
Depreciation in excess of capital allowances for period	1,954	1,893
Total tax charge for the financial year (Note 5 (a))	<u>73,196</u>	<u>86,248</u>

6. Tangible assets

	Land and buildings freehold €	Fixtures, fittings and equipment €	Motor vehicles €	Total €
Cost				
At 1 September 2024	1,513,989	485,309	11,033	2,010,331
Additions	48,394	-	-	48,394
At 31 August 2025	<u>1,562,383</u>	<u>485,309</u>	<u>11,033</u>	<u>2,058,725</u>
Depreciation				
At 1 September 2024	139,834	279,870	11,033	430,737
Charge for the financial year	15,624	34,406	-	50,030
At 31 August 2025	<u>155,458</u>	<u>314,276</u>	<u>11,033</u>	<u>480,767</u>
Net book value				
At 31 August 2025	<u>1,406,925</u>	<u>171,033</u>	<u>-</u>	<u>1,577,958</u>
At 31 August 2024	<u>1,374,155</u>	<u>205,439</u>	<u>-</u>	<u>1,579,594</u>

David Hynes Pharmacy (Roscommon) Ltd

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 31 August 2025

7. Stocks	2025	2024
	€	€
Finished goods and goods for resale	540,919	543,272
	<u> </u>	<u> </u>
The replacement cost of stock did not differ significantly from the figures shown.		
8. Debtors	2025	2024
	€	€
Trade debtors	221,454	212,686
Amounts owed by group undertakings	4,507,566	3,742,566
Other debtors	100,500	100,500
Taxation	139,153	132,473
	<u> </u>	<u> </u>
	4,968,673	4,188,225
	<u> </u>	<u> </u>
9. Creditors	2025	2024
Amounts falling due within one year	€	€
Trade creditors	268,846	236,299
Taxation	115,322	136,213
Other creditors	1,278	5,294
Accruals	7,500	12,892
	<u> </u>	<u> </u>
	392,946	390,698
	<u> </u>	<u> </u>
10. Income Statement		
	2025	2024
	€	€
At 1 September 2024	8,171,975	7,584,554
Profit for the financial year	495,058	587,421
	<u> </u>	<u> </u>
At 31 August 2025	8,667,033	8,171,975
	<u> </u>	<u> </u>
11. Capital commitments		
The company had no material capital commitments at the financial year-ended 31 August 2025.		
12. Directors' remuneration	2025	2024
	€	€
Remuneration	137,975	117,741
Pension contributions	105,634	26,695
	<u> </u>	<u> </u>
	243,609	144,436
	<u> </u>	<u> </u>
13. Post-Balance Sheet Events		
There have been no significant events affecting the company since the financial year-end.		
14. Approval of financial statements		
The financial statements were approved and authorised for issue by the board of directors on 6 March 2026.		